닫기
검색

Pipeline

Filters
Pipeline
NN2101
Indications
Neovascular Retinal Diseases
Hashtag
#HIF #NeuroProtection #FirstInClass #OnlyOneInTheGlobe
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Fully human IgG1 monoclonal antibody discovered by Novelty Nobility
Target
c-Kit (CD117 or Stem Cell Factor Receptor)
Science
Unlike most investigational retinal therapies which are currently participating in a race to increase the durability of anti-VEGF therapies, we focus on the fundamentals of the retinal diseases — hypoxia. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor stabilized by hypoxia, playing a pivotal role in the onset and development of retinal diseases. Interestingly, our c-Kit inhibitor NN2101 regulates HIF-1α and mediates vascular permeability, inducing vessel normalization and resolution of hypoxia. We dream of curing retinal diseases.

Publications

1. [ARVO Poster] The novel function of NN2101, an anti-c-kit antibody, as an inhibitor of HIF via c-kit regulation in retinal neovascularization and neurodegeneration (2022)

2. [Pharmaceutics] A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological CNV in Mice (2021)

3. [ARVO Poster] A Fully Human Monoclonal Antibody Targeting c-KIT is a Potent Inhibitor of Choroidal Neovascularization in a Murine Model (2021)

4. [IJBIOMAC] Development and characterization of a fully human antibody targeting SCF/c-kit signaling (2020)

5. [ATVB] SCF (Stem Cell Factor) and cKIT Modulate Pathological Ocular Neovascularization (2019)

6. [Mol Vis.] Src tyrosine kinase regulates the stem cell factor-induced breakdown of the blood-retinal barrier (2016)

7. [ATVB] Stem Cell Factor Is a Potent Endothelial Permeability Factor (2014)

8. [Cardiovasc Res.] Direct and Differential Effects of Stem Cell Factor on the Neovascularization Activity of Endothelial Progenitor Cells (2011)


Pipeline
NN2802 / SLRN-517
Partnership
Indications
Mast Cell Diseases
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Fully human IgG1 monoclonal antibody discovered by Novelty Nobility
Target
c-Kit (CD117 or Stem Cell Factor Receptor)
Science
c-Kit is expressed in various cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. SCF/c-Kit signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Our anti-c-Kit antibody specifically binds c-Kit with high specificity and potently inhibits its activity.
Publications

1. [Mol. Cell. Biochem] A fully human anti‑c‑Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells (2022)

Pipeline
NN3201
Indications
c-Kit+ Solid & Hematologic Cancers
Hashtag
#CompleteRemission #ADC #Monotherapy #BestInClass
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Novel antibody-drug conjugate (ADC) designed and created by Novelty Nobility- Fully human IgG1 monoclonal antibody discovered by Novelty Nobility conjugated with ThioBridge®, a proprietary site-specific ADC cleavable linker technology of Abzena, and MMAE with DAR 4
Target
c-Kit (CD117 or Stem Cell Factor Receptor)
Science
Developed to treat both c-Kit wildtype and activating mutation-driven cancers, NN3201 monotherapy exhibited complete remission in all tested xenograft model studies of hard-to-treat cancers such as SCLC and AML. This novel ADC is powered by dual modalities that simultaneously address the tumor microenvironment (TME) via c-Kit pathway inhibition and by targeting c-Kit positive tumors for ADC internalization. NN3201 also demonstrates a superior preclinical safety profile with a large therapeutic index.
Publications

1. [AACR poster] An Optimized Preclinical Antibody-Drug Conjugate Against Cancers with cKIT Overexpression or Activating Mutations

2. [Int. J. Mol. Sci.] Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer (2022)

3. [Mol. Oncol.] A novel anti-c-Kit ADC to treat wild-type and activating-mutant c-Kit-positive tumors (2021)

Pipeline
NN3206
Indications
Pan RAS-driven Cancers
Hashtag
#PanRAS #ADC #TheNextReallyBigThing #FirstInClass
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Novel antibody-drug conjugate (ADC) created by Novelty Nobility
Target
Undisclosed
Science
An undruggable target from a traditional antibody perspective, RAS mutations regulate induction of a certain membrane protein, our undisclosed target. Pan RAS mutations and overexpression of our undisclosed target are found to be highly correlated in various RAS-driven tumors. As such, NN3206 is designed to demonstrate superb RAS subtype- or mutation-agnostic pharmacological activities.